Clinical Trials
9
Trial Phases
2 Phases
Drug Approvals
76
Drug Approvals
Isophane Protamine Human Insulin Injection
- Product Name
- 诺和灵N
- Approval Number
- S20201012
- Approval Date
- Feb 5, 2020
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
News
FDA Implements Import Alert to Combat Unsafe GLP-1 Drug Ingredient Imports Amid Obesity Treatment Shortage
The FDA has issued an import alert authorizing detention without physical examination of GLP-1 drug ingredient shipments at U.S. ports due to safety concerns about adulterated products.
WHO Adds GLP-1 Diabetes Drugs to Essential Medicines List, Excludes Weight-Loss Indication
The World Health Organization has added GLP-1 medications including semaglutide and tirzepatide to its essential medicines list for treating type 2 diabetes with comorbidities.
Aspen Pharmacare to Launch Generic Weight-Loss Drugs at Half the Price of Ozempic and Wegovy
Aspen Pharmacare, Africa's largest drugmaker, plans to release cheaper versions of weight-loss drugs like Ozempic and Wegovy starting next year.
Novo Nordisk Partners with Apollo Clinics to Launch Comprehensive Obesity Management Programme Across India
Novo Nordisk has announced a strategic collaboration with Apollo Clinics to launch a comprehensive obesity management programme across multiple Indian cities, addressing the growing burden of overweight and obesity through a structured, multi-tiered care model.
FDA Accepts First Non-Invasive Surrogate Endpoint for MASH Clinical Trials
The FDA has accepted Echosens' Letter of Intent to qualify liver stiffness measurement by FibroScan® as the first non-invasive surrogate endpoint for MASH clinical trials.
Real-World Evidence Demonstrates Superior Cardiovascular and Renal Benefits of GLP-1 Receptor Agonists in High-Risk Patients
Real-world studies presented at ESC 2025 showed GLP-1 receptor agonists significantly reduced all-cause mortality, heart failure, and kidney dysfunction compared to sitagliptin in patients with type 2 diabetes and chronic kidney disease.
Eli Lilly Partners with JD Health for Direct-to-Consumer GLP-1 Drug Sales in China
Eli Lilly has partnered with Chinese online healthcare platform JD Health International to sell its obesity and diabetes drugs through direct-to-consumer channels in China.
Novo Nordisk Partners with Replicate Bioscience in $550M Self-Replicating RNA Deal for Obesity and Diabetes
Novo Nordisk has entered a $550 million partnership with California-based Replicate Bioscience to develop RNA-based treatments for obesity and diabetes using self-replicating RNA technology.
Teva Launches First Generic GLP-1 Weight Loss Drug as FDA Approves Generic Saxenda
Teva Pharmaceuticals received FDA approval and launched the first-ever generic GLP-1 receptor agonist indicated for weight loss in the United States.
FDA Issues Form 483 to Novo Nordisk's Bloomington Plant Over Contamination and Safety Violations
The FDA issued a Form 483 to Novo Nordisk's Bloomington, Indiana manufacturing facility following an inspection that identified contamination issues including cat and human hair in vial stoppers and pest infestations in classified areas.